A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells

M Toyoda, H Takagi, N Horiguchi, S Kakizaki, K Sato, H Takayama, M Mori

Background and aims: Induction of apoptosis of cancer cells through ligands of nuclear hormone receptors (NHRs) is a new approach in cancer therapy. Recently, one of the NHRs, peroxisome proliferator activated receptor γ (PPARγ), has been shown to influence cell growth in certain cancer cells although its effect on hepatocellular carcinoma (HCC) has not been analysed.

Methods: Experiments were conducted using three human liver cancer cell lines, PLC/PRF/5, Hep G2 and HuH-7, in vitro. These cells were exposed to troglitazone, a synthetic ligand for PPARγ, and the effects on cell growth were analysed.

Results: Expression of PPARγ mRNA was detected in all three liver cancer cell lines. Activation of PPARγ by troglitazone caused a marked growth inhibition in a dose dependent manner in three hepatoma cell lines. The DNA fragmentation ELISA assay and Hoechst 33258 staining revealed that the growth inhibitory effect by adding troglitazone was due to apoptosis of PLC/PRF/5, which strongly expressed PPARγ. Troglitazone also induced activation of the cell death protease, caspase 3, but not caspase 8, in PLC/PRF/5 cells. However, expression levels of antiapoptotic factor bcl-2 and apoptosis inducing factor bax were not affected.

Conclusion: Our study showed that PPARγ was expressed in human liver cancer cells and that the ligand for PPARγ, troglitazone, inhibited the growth of these cells by inducing apoptosis through caspase 3 activation, indicating that troglitazone could be potentially useful as an apoptosis inducer for the treatment of HCC.
Life Science, Buckinghamshire, UK), followed by ultraviolet cross linking. Hybridisation was carried out at 42°C for 12 hours with 32P labelled cDNA probes. The probe for human PPARγ was kindly provided by Dr Spiegelmann.

**Quantification of DNA fragmentation by ELISA**

DNA fragmentation was measured using a cellular DNA fragmentation ELISA kit (Roche Diagnosis, Mannheim, Germany), as described in the protocol provided by the manufacturer. Briefly, liver cancer cell line PLC/PRF/5 was adjusted to 1×10^6 cells/well in a microtitre plate. After overnight BrdU labelling, cells were treated with 0, 5, 10, and 100 µM of troglitazone for 72 hours. Cells were lysed and the microtitre plate was centrifuged at 250 g for 10 minutes. Then, 100 µl of the supernatant were removed and analysed by ELISA, using the instructions recommended by the manufacturer.

**Detection of apoptotic cells**

Nuclear morphology was assessed using Hoechst staining. PLC/PRF/5 was incubated with 20 µM of troglitazone for 72 hours. Cells were washed with Dulbecco’s modified Eagle’s medium and labelled with Hoechst 33258 (Sigma) for 10 minutes. The cells were examined by fluorescence microscopy. Apoptotic cells were distinguished by their characteristic patterns of nuclear condensation, cytoplasmic rounding.

**Detection of caspase activity**

PLC/PRF/5 was treated with troglitazone for 48 hours and activation of caspase 3 and caspase 8 was analysed using 250 µg of cell lysate by the colorimetric protease assay kit (MBL, Aichi, Japan), as recommended by the manufacturer. The activity of caspase was converted through measurement of absorbance (OD 405 values) using a microplate reader at 405 nm. Non-specific reaction was corrected by subtracting the background readings from the combination of cell lysates and buffers.

**Western blot analysis**

To determine protein expression of bcl-2 and bax, western blot analysis was performed. PLC/PRF/5, treated with various concentrations of troglitazone for 96 hours, was lysed in lysis buffer (10 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 0.1% sodium dodecyl sulphate, 0.1% deoxycholic acid, and protease inhibitor mixture). Following centrifugation at 14000 rpm at 4°C for 15 minutes, the protein concentration of the supernatants was determined using the Bio-Rad protein assay kit (Bio-Rad, Hercules, California, USA). A total of 30 µg of protein per lane was run on sodium dodecyl sulphate-polyacrylamide gel electrophoresis and then transferred onto nitrocellulose membranes for western blotting (Trans-Blot Transfer Medium; Bio-Rad). Membranes were blocked overnight at 4°C in a milk blocking buffer (5% non-fat dry milk). The blots were then probed for two hours with primary antibody (Ab) diluted in blocking buffer (20 mM Tris HCl, pH 7.4, 150 mM NaCl solution containing 0.1% Tween 20). Rabbit anti-bcl-2 polyclonal Ab (Calbiochem, San Diego, California, USA; diluted 1/500), mouse anti-bax monoclonal Ab (Santa Cruz Biotechnology, Santa Cruz, California, USA; diluted 1/100), and mouse anti-β-actin monoclonal Ab (Sigma; diluted 1/2000) were used. Following five washes, the blots were incubated for one hour with horseradish peroxidase conjugated secondary Ab (Toyobo, Osaka, Japan; diluted 1/2000). After additional washing, membranes were developed by western blotting luminol reagent from Santa Cruz Biotechnology.

**Statistical analysis**

Results are expressed as mean (SD). Statistical analysis was performed by repeated measures analysis of variance followed by Fisher’s PLSD test. A value of p<0.05 was considered statistically significant.

![Figure 1](http://gutjnl.com)  
**Figure 1** Northern blot analysis revealed peroxisome proliferator activated receptor γ (PPARγ) expression in all three liver cancer cell lines (PLC/PRF/5, Hep G2, and HuH-7). The expression level of PPARγ mRNA was higher in PLC/PRF/5 than in Hep G2 or HuH-7.

**RESULTS**

**Expression of PPARγ in human liver cell lines**

Although recent data showed that several cell lines of colon cancer, breast cancer, prostate cancer, and gastric cancer expressed PPARγ mRNA, the expression of PPARγ mRNA in liver cancer cell lines has not been studied. Expression of PPARγ mRNA was detected by northern blot analysis in all three liver cancer cell lines used in the present study (fig 1). The expression level of PPARγ was higher in PLC/PRF/5 than in the two other cell lines (Hep G2 and HuH-7).

**Troglitazone inhibits growth of liver cancer cells in vitro**

Three liver cancer cell lines were continuously cultured in the presence of various concentrations of troglitazone to investigate the effect of troglitazone on cell growth. Significantly, troglitazone markedly inhibited cell growth in all three cell lines. The growth inhibitory effect of troglitazone on PLC/PRF/5 was similar to that on HuH-7 with an effective dose (EC50) of 10 µM (fig 2A). In contrast, Hep G2 was less sensitive to the inhibitory effect of troglitazone than HuH-7 and PLC/PRF/5 (120 hours). Treatment with 10 µM of troglitazone resulted in significant growth inhibition in all three cell lines in time course studies over 120 hours (fig 2B).

**Troglitazone induces cell apoptosis**

As the growth inhibitory effect of troglitazone is reported to be due in part to induction of apoptosis,11 we carried out the following experiments. Culture of PLC/PRF/5 for 72 hours in the presence of 10, 50, or 100 µM of troglitazone was associated with cellular DNA fragmentation measured by ELISA, which increased proportionately with increasing concentrations of troglitazone (fig 3). We also evaluated chromatin morphology using Hoechst 33258 staining (fig 4). PLC/PRF/5 treated with 20 µM of troglitazone for 72 hours showed morphological features of apoptosis. In contrast, untreated cells maintained normal chromatin patterns and cell size. The number of apoptotic cells was proportional to the dose of troglitazone (data not shown).
Troglitazone activates caspase 3 but not caspase 8

As apoptosis of cells usually involves activation of cysteine proteases of the caspase family, we analysed the effect of troglitazone on activation of caspase 3 and/or caspase 8 in liver cancer cells. Treatment of PLC/PRF/5 for 48 hours with 5 or 10 µM of troglitazone resulted in a significant increase in the activity of caspase 3, and the increase was dose dependent (p<0.01) (fig 5). On the other hand, the activity of caspase 8 was not influenced by treatment with troglitazone (fig 5).

Western blot analysis showed that protein expression levels of bcl-2 and bax in PLC/PRF/5 were not changed by treatment with various concentrations of troglitazone for 96 hours (fig 6).

DISCUSSION

It has been shown that PPARγ plays an important role as a regulator of lipid metabolism and a key mediator of lipid storage. Recently, the synthetic reagent troglitazone, which was originally developed as a therapeutic agent for diabetes mellitus, has been demonstrated to act as a relatively high affinity ligand for PPARγ, and exerts growth inhibitory effects on colon cancer, breast cancer, prostate cancer, and gastric cancer. However, to our knowledge, the role of PPARγ in liver cancer cells has not been discussed previously. In the present

Figure 2. (A) Effect of troglitazone on the growth of liver cancer cell lines. The growth of all three liver cancer cell lines was inhibited by troglitazone treatment in a dose dependent manner. Data are presented as per cent growth relative to untreated cells (120 hours). (B–D) Time course of inhibition of cell growth by troglitazone. Treatment with 10 µM of troglitazone resulted in significant growth inhibition of all three cell lines (PLC/PRF/5 (B), Hep G2 (C), and HuH-7 (D)) up to 120 hours.

Figure 3. DNA fragmentation by ELISA assay, as measured by absorbance (OD 450 values). Culture of PLC/PRF/5 for 72 hours in the presence of troglitazone resulted in significant DNA fragmentation.
study, we analysed the effect of troglitazone on growth and induction of apoptosis of liver cancer cells in vitro.

Our results showed that PPARγ mRNA was expressed at various levels in all three liver cancer cell lines. Furthermore, we also demonstrated that the growth of liver cancer cell lines was inhibited by troglitazone in a dose dependent manner. However, the rank order of the sensitivity to troglitazone did not correspond to the levels of PPARγ expression in these cells. HepG2, which expressed the same level of PPARγ mRNA as HuH-7, was relatively insensitive to the growth inhibitory effect of troglitazone. That the expression level of PPARγ does not parallel the growth inhibitory effect of the ligand is in agreement with the results of Elstner and colleagues and Mueller and colleagues. Interestingly, the growth inhibitory effects of troglitazone were observed at concentrations equivalent to those detected in patients with insulin resistant diabetes mellitus treated with the same agent. This finding suggests that the clinical dose of troglitazone can potentially inhibit the growth of liver cancer cells.

To determine the underlying mechanisms of the growth inhibitory effect of troglitazone, we investigated whether troglitazone acts by inducing apoptosis of liver cancer cells. For this purpose, we performed DNA fragmentation assay and Hoechst staining. In both assays, troglitazone induced apoptosis of PLC/PRF/5 in a dose dependent manner. Chinetti and colleagues also reported that troglitazone induced apoptosis of human monocyte derived macrophages. However, other reports showed that apoptosis was not a major mechanism by which troglitazone induced cell growth inhibition but that differentiation of cancer cells by the ligand was the major mechanism.

We also analysed the mechanisms of troglitazone induced apoptosis. Results from our study demonstrated that troglitazone activated caspase 3 but not caspase 8, which are cysteine proteases of the caspase family. We hypothesised that such activation of caspase 3 might indicate that apoptosis was mainly regulated by mitochondria related apoptosis factor. However, expression levels of antiapoptotic factor bcl-2 and apoptosis inducing factor bax were not overtly affected by troglitazone treatment. In this regard, Elstner and colleagues also reported that troglitazone induced apoptosis of human monocyte derived macrophages. However, other reports showed that apoptosis was not a major mechanism by which troglitazone induced cell growth inhibition but that differentiation of cancer cells by the ligand was the major mechanism.

Figure 4 Detection of apoptosis of PLC/PRF/5 cells by Hoechst 33258 staining. PLC/PRF/5 treated with 20 µM of troglitazone for 72 hours showed morphological features of apoptosis. In contrast, untreated cells maintained normal chromatin patterns and cell size (original magnification ×200).

Figure 5 Effect of troglitazone on caspases 3 (A) and 8 (B) in PLC/PRF/5 cells. PLC/PRF/5 cells were treated for 48 hours with 5 or 10 µM of troglitazone. The activity of caspase 3, but not that of caspase 8, was significantly increased in response to troglitazone in a dose dependent manner. **p<0.01.

Figure 6 Effect of troglitazone on expression of bcl-2 and bax. Western blot analysis demonstrated that expression levels of bcl-2 and bax in PLC/PRF/5 were not changed by treatment with troglitazone for 96 hours.
reported that exposure of human breast cancer cells to a combination of troglitazone and all-trans-retinoic acid decreased bcl-2 protein to nearly undetectable levels.

Recent studies have examined the relationship between activation of PPARγ and nuclear factor kappa B (NFκB). NFκB is a DNA binding protein that augments the transcription of various genes involved in cell proliferation and plays an important role in cell development, survival, and oncogenesis.1–4 In this respect, Chinetti and colleagues5 suggested that PPARγ induced cellular apoptosis by interfering negatively with the antiapoptotic NFκB signalling pathway. Further studies are needed to elucidate the exact mechanisms of troglitazone induced apoptosis of liver cancer cells.

Hepatocellular carcinoma is a major cause of cancer related mortality in the world and the number of new cases with this disease has mainly focused on surgical resection, embolisation therapy, and ethanol injection; these therapies are far generally less favourable than other cancers. Treatment for this disease is generally less favourable than other cancers. For patients with liver cancer. However, assessment of the clinical utility of this agent should await more thorough analysis of its local and systemic effects as troglitazone induced liver injury has been documented in recent studies.5–8

In summary, in the present study we have demonstrated expression of PPARγ in human liver cancer cells. Our results also showed that the ligand for PPARγ, troglitazone, inhibited cell growth and induced apoptosis. The latter findings suggest that this agent might be potentially useful in the treatment of liver cancer.

Authors’ affiliations
M Toyoda, H Takagi, N Horiguchi, S Kakizaki, K Sato, H Takayama, M Mori, First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, Japan

REFERENCES
A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells

M Toyoda, H Takagi, N Horiguchi, S Kakizaki, K Sato, H Takayama and M Mori

Gut 2002 50: 563-567
doi: 10.1136/gut.50.4.563

Updated information and services can be found at:
http://gut.bmj.com/content/50/4/563

These include:

References
This article cites 18 articles, 3 of which you can access for free at:
http://gut.bmj.com/content/50/4/563#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Hepatic cancer (474)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/